Cryo-Cell

Q3 FY2026 EarningsQ3 FY26 results beat consensus across most key metrics despite a revenue miss. Revenue was $7.82M vs. $7.45M expected (+4.98%), while EPS (GAAP) of $0.16 significantly outperformed the $0.03 consensus. Operating income (EBIT) reached $2.19M, substantially exceeding the $0.76M mean estimate, driven by a 10% YoY reduction in cost of sales and lower-than-anticipated interest expenses. Management maintains a cautious outlook due to the ongoing Duke University arbitration, which has paused the Cryo-Cell Institute expansion and the Celle Corp. spinoff.